COHERUS ONCOLOGY INC (CHRS) Fundamental Analysis & Valuation

NASDAQ:CHRS • US19249H1032

1.69 USD
-0.09 (-5.06%)
At close: Mar 12, 2026
1.74 USD
+0.05 (+2.96%)
After Hours: 3/12/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CHRS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Overall CHRS gets a fundamental rating of 2 out of 10. We evaluated CHRS against 519 industry peers in the Biotechnology industry. CHRS has a bad profitability rating. Also its financial health evaluation is rather negative. CHRS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. CHRS Profitability Analysis

1.1 Basic Checks

  • In the past year CHRS has reported negative net income.
  • In the past year CHRS has reported a negative cash flow from operations.
  • CHRS had negative earnings in 4 of the past 5 years.
  • In the past 5 years CHRS always reported negative operating cash flow.
CHRS Yearly Net Income VS EBIT VS OCF VS FCFCHRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

  • The Return On Assets of CHRS (30.00%) is better than 98.07% of its industry peers.
  • CHRS has a better Return On Equity (176.56%) than 99.61% of its industry peers.
Industry RankSector Rank
ROA 30%
ROE 176.56%
ROIC N/A
ROA(3y)-30.71%
ROA(5y)-23.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CHRS Yearly ROA, ROE, ROICCHRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 -600

1.3 Margins

  • Looking at the Profit Margin, with a value of 185.44%, CHRS belongs to the top of the industry, outperforming 98.84% of the companies in the same industry.
  • In the last couple of years the Profit Margin of CHRS has declined.
  • With a decent Gross Margin value of 47.79%, CHRS is doing good in the industry, outperforming 74.95% of the companies in the same industry.
  • CHRS's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 185.44%
GM 47.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-15.79%
GM growth 3Y-12.08%
GM growth 5Y-10.08%
CHRS Yearly Profit, Operating, Gross MarginsCHRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. CHRS Health Analysis

2.1 Basic Checks

  • CHRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for CHRS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CHRS Yearly Shares OutstandingCHRS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CHRS Yearly Total Debt VS Total AssetsCHRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of -4.00, we must say that CHRS is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of CHRS (-4.00) is comparable to the rest of the industry.
  • CHRS has a Debt/Equity ratio of 0.58. This is a neutral value indicating CHRS is somewhat dependend on debt financing.
  • CHRS has a Debt to Equity ratio of 0.58. This is in the lower half of the industry: CHRS underperforms 70.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Altman-Z -4
ROIC/WACCN/A
WACC8.77%
CHRS Yearly LT Debt VS Equity VS FCFCHRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • CHRS has a Current Ratio of 1.24. This is a normal value and indicates that CHRS is financially healthy and should not expect problems in meeting its short term obligations.
  • CHRS has a Current ratio of 1.24. This is amonst the worse of the industry: CHRS underperforms 83.62% of its industry peers.
  • CHRS has a Quick Ratio of 1.23. This is a normal value and indicates that CHRS is financially healthy and should not expect problems in meeting its short term obligations.
  • CHRS has a worse Quick ratio (1.23) than 83.43% of its industry peers.
Industry RankSector Rank
Current Ratio 1.24
Quick Ratio 1.23
CHRS Yearly Current Assets VS Current LiabilitesCHRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CHRS Growth Analysis

3.1 Past

  • CHRS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -81.33%.
EPS 1Y (TTM)-81.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-76.46%

3.2 Future

  • CHRS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.97% yearly.
  • Based on estimates for the next years, CHRS will show a very strong growth in Revenue. The Revenue will grow by 57.12% on average per year.
EPS Next Y28.3%
EPS Next 2Y17.69%
EPS Next 3Y5.07%
EPS Next 5Y15.97%
Revenue Next Year79.63%
Revenue Next 2Y52.01%
Revenue Next 3Y62.36%
Revenue Next 5Y57.12%

3.3 Evolution

CHRS Yearly Revenue VS EstimatesCHRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
CHRS Yearly EPS VS EstimatesCHRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. CHRS Valuation Analysis

4.1 Price/Earnings Ratio

  • CHRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CHRS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CHRS Price Earnings VS Forward Price EarningsCHRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CHRS Per share dataCHRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.69%
EPS Next 3Y5.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CHRS Dividend Analysis

5.1 Amount

  • CHRS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CHRS Fundamentals: All Metrics, Ratios and Statistics

COHERUS ONCOLOGY INC

NASDAQ:CHRS (3/12/2026, 8:00:01 PM)

After market: 1.74 +0.05 (+2.96%)

1.69

-0.09 (-5.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-09
Earnings (Next)05-11
Inst Owners33.44%
Inst Owner Change-1.47%
Ins Owners5.23%
Ins Owner Change-0.1%
Market Cap252.60M
Revenue(TTM)N/A
Net Income(TTM)154.97M
Analysts83.33
Price Target5.78 (242.01%)
Short Float %31.16%
Short Ratio12.92
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.95%
Min EPS beat(2)-12.36%
Max EPS beat(2)0.45%
EPS beat(4)1
Avg EPS beat(4)-42.18%
Min EPS beat(4)-108.91%
Max EPS beat(4)0.45%
EPS beat(8)3
Avg EPS beat(8)-57.9%
EPS beat(12)6
Avg EPS beat(12)-36.26%
EPS beat(16)8
Avg EPS beat(16)-35.21%
Revenue beat(2)0
Avg Revenue beat(2)-8.12%
Min Revenue beat(2)-15.42%
Max Revenue beat(2)-0.81%
Revenue beat(4)1
Avg Revenue beat(4)-22.58%
Min Revenue beat(4)-86.37%
Max Revenue beat(4)12.3%
Revenue beat(8)3
Avg Revenue beat(8)-10.27%
Revenue beat(12)4
Avg Revenue beat(12)-11.09%
Revenue beat(16)4
Avg Revenue beat(16)-11.88%
PT rev (1m)0%
PT rev (3m)13.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.72%
EPS NY rev (1m)0%
EPS NY rev (3m)1.6%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)-1.75%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.02
P/FCF N/A
P/OCF N/A
P/B 2.88
P/tB 6.6
EV/EBITDA N/A
EPS(TTM)-1.36
EYN/A
EPS(NY)-0.98
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0.56
BVpS0.59
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 30%
ROE 176.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 185.44%
GM 47.79%
FCFM N/A
ROA(3y)-30.71%
ROA(5y)-23.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-15.79%
GM growth 3Y-12.08%
GM growth 5Y-10.08%
F-Score4
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.24
Quick Ratio 1.23
Altman-Z -4
F-Score4
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-81.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.43%
EPS Next Y28.3%
EPS Next 2Y17.69%
EPS Next 3Y5.07%
EPS Next 5Y15.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-76.46%
Revenue Next Year79.63%
Revenue Next 2Y52.01%
Revenue Next 3Y62.36%
Revenue Next 5Y57.12%
EBIT growth 1Y-33.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-87.59%
EBIT Next 3Y12.47%
EBIT Next 5Y7.38%
FCF growth 1Y65.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.55%
OCF growth 3YN/A
OCF growth 5YN/A

COHERUS ONCOLOGY INC / CHRS FAQ

What is the ChartMill fundamental rating of COHERUS ONCOLOGY INC (CHRS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CHRS.


What is the valuation status of COHERUS ONCOLOGY INC (CHRS) stock?

ChartMill assigns a valuation rating of 0 / 10 to COHERUS ONCOLOGY INC (CHRS). This can be considered as Overvalued.


Can you provide the profitability details for COHERUS ONCOLOGY INC?

COHERUS ONCOLOGY INC (CHRS) has a profitability rating of 3 / 10.


What is the expected EPS growth for COHERUS ONCOLOGY INC (CHRS) stock?

The Earnings per Share (EPS) of COHERUS ONCOLOGY INC (CHRS) is expected to grow by 28.3% in the next year.